Related Experiment Video
Updated: Feb 10, 2026

Capture and Release of Viable Circulating Tumor Cells from Blood
Published on: October 28, 2016
Editorial Commentary: Caveat Flexor-To Release or Not to Release the Iliopsoas, That Is the Question
Abstract:
In nonarthritic patients with femoroacetabular impingement syndrome, borderline dysplasia, and symptomatic iliopsoas snapping, arthroscopic iliopsoas fractional lengthening carries a significant risk of postarthroscopic instability. The iliopsoas is a dynamic stabilizer of the anterior hip. Thus, although statistically significant and clinically important improvements in hip function have the potential to be achieved with iliopsoas fractional lengthening, surgeons must be supremely confident in their ability to perform a secure capsular plication, labral preservation (not debridement), comprehensive cam correction, avoidance of intra-abdominal fluid extravasation, release of all iliopsoas tendon bands (if bifid or trifid), and ensure that femoral version is normal or low, neck-shaft angle is not excessively valgus, the dysplasia magnitude is no more than mild, and that there is no excessive soft tissue hypermobility. If these goals can be met, then excellent outcomes can be achieved. If not, then an iliopsoas fractional lengthening should not be performed.
Related Concept Videos
Energy-releasing Steps of Glycolysis
The first energy-releasing step—the 6th step of glycolysis...
ATP Energy Storage and Release
One example of energy coupling using ATP involves a...
Drugs Affecting Neurotransmitter Release or Uptake
In Vitro Drug Release Testing: Overview, Development and Validation
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
The Sense of Self: Reflected Self-Appraisal and Social Comparison

